Jan 15
心脏生物科技解决方案激活MyCardia AT中国生产流程并进入NMPA最终申报阶段
CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.
Jan 15
CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.
Sep 25
CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.
Sep 11
CBSC secures $375K purchase order with Noventis Medical and launches recurring revenue program for MyCardia AT devices.
Sep 04
Cardiac Biotech Solutions, Inc. signs $600K exclusive distribution deal with Noventis Medical, expanding cardiac monitoring reach into Latin America.
May 08
CB Scientific, Inc. is now Cardiac Biotech Solutions, Inc., reflecting our mission to deliver advanced, cloud-connected cardiac monitoring technologies across global healthcare markets.
Feb 25
CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.
Dec 14
Updates to provide device improvements while maintaining the innovative core-functionality of CBSC’s state of the art cardiac event monitor.